Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ABBV-383 Monotherapy in Japanese Relapsed/Refractory Multiple Myeloma
jRCT2011210079Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Number of Dose-Limiting Toxicities (DLT) and Number of Participants with Adverse Events (AE). Started May 2022; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2011210079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210079.